{"id":32079,"date":"2025-07-23T14:40:26","date_gmt":"2025-07-23T21:40:26","guid":{"rendered":"https:\/\/getheally.com\/patients\/news\/what-is-the-tirzepatide-starting-dose-for-weight-loss-copy"},"modified":"2025-10-28T14:15:42","modified_gmt":"2025-10-28T21:15:42","slug":"what-is-the-tirzepatide-starting-dose-for-weight-loss","status":"publish","type":"post","link":"https:\/\/getheally.com\/patients\/news\/what-is-the-tirzepatide-starting-dose-for-weight-loss","title":{"rendered":"What is the Tirzepatide Starting Dose for Weight Loss?"},"content":{"rendered":"

Tirzepatide<\/a> is a dual GIP\/GLP\u20111 receptor agonist gaining attention for its potential in weight management. If you\u2019re looking to get started, it\u2019s important to understand the <\/span>tirzepatide starting dose<\/span> and the dosing schedule<\/a>.\u00a0<\/span><\/span><\/p>\n

Patients often begin with 2.5\u202fmg once weekly, which serves as an introductory dose to help the body adapt and may reduce early side effects like mild gastrointestinal discomfort<\/span>.<\/p>\n

A healthcare provider typically evaluates response\u2014such as tolerability, side effects, appetite, and weight changes\u2014before recommending a gradual dosing adjustment.<\/span><\/p>\n

Active Ingredient: Tirzepatide<\/h4>\n

Tirzepatide is a dual agonist \u2014 it activates GLP-1 receptors and<\/em> GIP (glucose-dependent insulinotropic polypeptide) receptors. The added GIP activity may enhance weight loss and blood sugar control compared to GLP-1\u2013only drugs.<\/p>\n

In the U.S., Tirzepatide is available as: Mounjaro<\/a> and Zepbound<\/a> <\/span><\/p>\n

\n
\n\n\n\n\n\n\n
Brand Name<\/th>\nManufacturer<\/th>\nRoute<\/th>\nFDA-Approved Use<\/th>\nFDA Approval Year<\/th>\n<\/tr>\n<\/thead>\n
Mounjaro<\/td>\nEli Lilly<\/td>\nInjectable (weekly)<\/td>\nType 2 diabetes<\/td>\n2022<\/td>\n<\/tr>\n
Zepbound<\/td>\nEli Lilly<\/td>\nInjectable (weekly)<\/td>\nChronic weight management<\/td>\n2023<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Throughout this article, any reference to Tirzepatide for weight loss refers to Zepbound. Mentions of Tirzepatide for blood sugar control refer to Mounjaro.<\/p>\n<\/div>\n<\/div>\n

Typical Dose Adjustment Schedule<\/h2>\n

Below is a tirzepatide dose chart to help you understand the schedule outlined by Eli Lilly<\/a>, the manufacturer of both Mounjaro and Zepbound.\u00a0<\/span>Tirzepatide doses are frequently evaluated every 4 weeks to monitor for side effects and efficacy.<\/span><\/p>\n\n\n\n\n\n\n\n\n\n
\n

Tirzepatide Starting Dose<\/b><\/h4>\n<\/td>\n

\n

Dosage Increase<\/b><\/h4>\n<\/td>\n

\n

Increase Schedule<\/b><\/h4>\n<\/td>\n

\n

New Tirzepatide Dose<\/b><\/h4>\n<\/td>\n<\/tr>\n

2.5 mg\/0.5 mL<\/span><\/td>\n+2.5 mg<\/span><\/td>\nWeek 1-4<\/span><\/td>\n5 mg\/0.5 mL<\/span><\/td>\n<\/tr>\n
5 mg\/0.5 mL<\/span><\/td>\n+2.5 mg<\/span><\/td>\nWeek 5-8<\/span><\/td>\n7.5 mg\/0.5 mL<\/span><\/td>\n<\/tr>\n
7.5 mg\/0.5 mL<\/span><\/td>\n+2.5 mg<\/span><\/td>\nWeek 9-12<\/span><\/td>\n10 mg\/0.5 mL<\/span><\/td>\n<\/tr>\n
10 mg\/0.5 mL<\/span><\/td>\n+2.5 mg<\/span><\/td>\nWeek 13-17<\/span><\/td>\n12.5 mg\/0.5 mL<\/span><\/td>\n<\/tr>\n
12.5 mg\/0.5 mL<\/span><\/td>\n+2.5 mg<\/span><\/td>\nWeek 18-21<\/span><\/td>\n15 mg\/0.5 mL<\/span><\/td>\n<\/tr>\n
15 mg\/0.5 mL<\/span><\/td>\nN\/A<\/span><\/td>\nWeek 21+\u00a0<\/span><\/td>\nN\/A<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/h2>\n

Clinical Trial Evidence<\/h2>\n

SURMOUNT\u20111 (Phase\u202f3)<\/h4>\n